| scholarly article | Q13442814 |
| P50 | author | Ana Martínez | Q30506374 |
| Angel Santos | Q40437528 | ||
| Ana Perez-Castillo | Q40437571 | ||
| Marta Cortes-Canteli | Q117232080 | ||
| Rosario Luna-Medina | Q117232082 | ||
| P2093 | author name string | Mercedes Alonso | |
| P2860 | cites work | Peroxisome proliferator-activated receptor gamma ligands suppress the transcriptional activation of cyclooxygenase-2. Evidence for involvement of activator protein-1 and CREB-binding protein/p300. | Q38302731 |
| P433 | issue | 22 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | inflammation | Q101991 |
| P1104 | number of pages | 10 | |
| P304 | page(s) | 21453-21462 | |
| P577 | publication date | 2005-04-06 | |
| P1433 | published in | Journal of Biological Chemistry | Q867727 |
| P1476 | title | Regulation of inflammatory response in neural cells in vitro by thiadiazolidinones derivatives through peroxisome proliferator-activated receptor gamma activation | |
| P478 | volume | 280 |
| Q27005806 | A new look at auranofin, dextromethorphan and rosiglitazone for reduction of glia-mediated inflammation in neurodegenerative diseases |
| Q37801966 | Administration of thiazolidinediones for neuroprotection in ischemic stroke: a pre-clinical systematic review. |
| Q37211800 | Agonism of Peroxisome Proliferator Receptor-Gamma may have Therapeutic Potential for Neuroinflammation and Parkinson's Disease |
| Q28075617 | Alzheimer Disease: Crosstalk between the Canonical Wnt/Beta-Catenin Pathway and PPARs Alpha and Gamma |
| Q36657652 | Autoimmune modulation of astrocyte-mediated homeostasis. |
| Q29994589 | Bridging Type 2 Diabetes and Alzheimer's Disease: Assembling the Puzzle Pieces in the Quest for the Molecules With Therapeutic and Preventive Potential |
| Q38916940 | CCAAT/enhancer binding protein β directly regulates the expression of the complement component 3 gene in neural cells: implications for the pro-inflammatory effects of this transcription factor. |
| Q61849157 | CD200R1 and CD200 expression are regulated by PPAR-γ in activated glial cells |
| Q37657490 | Crosstalk between phosphodiesterase 7 and glycogen synthase kinase-3: two relevant therapeutic targets for neurological disorders |
| Q95763679 | Curcumin Protects Neuron against Cerebral Ischemia-Induced Inflammation through Improving PPAR-Gamma Function |
| Q55088439 | Demyelination in Multiple Sclerosis: Reprogramming Energy Metabolism and Potential PPARγ Agonist Treatment Approaches. |
| Q37878285 | Do PPAR-Gamma Agonists Have a Future in Parkinson's Disease Therapy? |
| Q21135583 | Docosahexaenoic acid-derived neuroprotectin D1 induces neuronal survival via secretase- and PPARγ-mediated mechanisms in Alzheimer's disease models |
| Q36931609 | Drug insight: effects mediated by peroxisome proliferator-activated receptor-gamma in CNS disorders |
| Q37287524 | Effect of pioglitazone on neuropathic pain and spinal expression of TLR-4 and cytokines |
| Q46293996 | Effects of cannabidiol interactions with Wnt/β-catenin pathway and PPARγ on oxidative stress and neuroinflammation in Alzheimer's disease |
| Q38209880 | Effects of lithium on inflammation |
| Q34084682 | Endocannabinoids in synaptic plasticity and neuroprotection |
| Q36317708 | Entorhinal cortical neurons are the primary targets of FUS mislocalization and ubiquitin aggregation in FUS transgenic rats |
| Q61812962 | Exploiting the Therapeutic Potential of Endogenous Immunomodulatory Systems in Multiple Sclerosis-Special Focus on the Peroxisome Proliferator-Activated Receptors (PPARs) and the Kynurenines |
| Q36896228 | Extracts of Tripterygium wilfordii Hook F in the Treatment of Rheumatoid Arthritis: A Systemic Review and Meta-Analysis of Randomised Controlled Trials |
| Q36415259 | Glycogen synthase kinase 3 inhibition promotes adult hippocampal neurogenesis in vitro and in vivo. |
| Q35134523 | ID4 mediates proliferation of astrocytes after excitotoxic damage in the mouse hippocampus |
| Q35908493 | Identification and characterization of small molecule antagonists of pRb inactivation by viral oncoproteins |
| Q37310621 | Immunomodulatory and anti-inflammatory effects of chondroitin sulphate |
| Q40576825 | Impact and Therapeutic Potential of PPARs in Alzheimer's Disease |
| Q59791359 | Influence of High-Fat Diets Consumed During the Juvenile Period on Hippocampal Morphology and Function |
| Q35193317 | Inhibition of COX-2 expression by endocannabinoid 2-arachidonoylglycerol is mediated via PPAR-γ. |
| Q28476019 | Inhibition of glioblastoma growth by the thiadiazolidinone compound TDZD-8 |
| Q35521795 | Inhibitory effect of a tyrosine-fructose Maillard reaction product, 2,4-bis(p-hydroxyphenyl)-2-butenal on amyloid-β generation and inflammatory reactions via inhibition of NF-κB and STAT3 activation in cultured astrocytes and microglial BV-2 cells |
| Q33877126 | Inhibitory effect of ent-Sauchinone on amyloidogenesis via inhibition of STAT3-mediated NF-κB activation in cultured astrocytes and microglial BV-2 cells |
| Q35804789 | Inhibitory effect of inflexinol on nitric oxide generation and iNOS expression via inhibition of NF-kappaB activation |
| Q37165497 | Insulin, insulin-like growth factors and incretins: neural homeostatic regulators and treatment opportunities |
| Q47687993 | Interactions Between the Canonical WNT/Beta-Catenin Pathway and PPAR Gamma on Neuroinflammation, Demyelination, and Remyelination in Multiple Sclerosis. |
| Q38779290 | Ionomycin induces prostaglandin E2 formation in murine osteoblastic MC3T3-E1 cells via mechanisms independent of its ionophoric nature |
| Q48314707 | Ischemic preconditioning reveals that GLT1/EAAT2 glutamate transporter is a novel PPARgamma target gene involved in neuroprotection. |
| Q36521858 | Managing psychiatric disorders with antidiabetic agents: translational research and treatment opportunities |
| Q38032481 | Modulating microglia activity with PPAR-γ agonists: a promising therapy for Parkinson's disease? |
| Q33575523 | Modulation of microglial innate immunity in Alzheimer's disease by activation of peroxisome proliferator-activated receptor gamma |
| Q45836442 | NFAT5-dependent expression of AQP4 in astrocytes. |
| Q48157997 | NP031112, a thiadiazolidinone compound, prevents inflammation and neurodegeneration under excitotoxic conditions: potential therapeutic role in brain disorders |
| Q37785813 | Neuroimmune Pharmacology of Neurodegenerative and Mental Diseases |
| Q48617615 | Neuroprotection against focal ischemic brain injury by the peroxisome proliferator-activated receptor-gamma agonist rosiglitazone |
| Q42952425 | PPAR activation has dichotomous control on the expression levels of cytosolic and secretory phospholipase A2 in astrocytes; inhibition in naïve, untreated cells and enhancement in LPS‐stimulated cells |
| Q34203838 | PPAR-alpha and PPAR-beta expression changes in the hippocampus of rats undergoing global cerebral ischemia/reperfusion due to PPAR-gamma status |
| Q36445372 | PPAR-gamma Pro12Ala genotype and risk of cognitive decline in elders |
| Q41938308 | PPAR-gamma, Microglial Cells, and Ocular Inflammation: New Venues for Potential Therapeutic Approaches |
| Q21342822 | PPAR-gamma: Therapeutic Potential for Multiple Sclerosis |
| Q40288794 | PPARs in Alzheimer's Disease |
| Q34491511 | PPARγ agonists promote oligodendrocyte differentiation of neural stem cells by modulating stemness and differentiation genes |
| Q90722520 | PPARγ and Cognitive Performance |
| Q35176258 | Pan-PPAR modulation effectively protects APP/PS1 mice from amyloid deposition and cognitive deficits |
| Q47739408 | Peroxisome proliferator-activated receptor γ (PPARγ): A master gatekeeper in CNS injury and repair |
| Q57714157 | Peroxisome proliferator-activated receptor γ ligands regulate neural stem cell proliferation and differentiation in vitro and in vivo |
| Q28742424 | Phosphodiesterase 7 inhibition preserves dopaminergic neurons in cellular and rodent models of Parkinson disease |
| Q34187919 | Pilot data on telmisartan short-term effects on glucose metabolism in the olfactory tract in Alzheimer's disease |
| Q58694525 | Pioglitazone use and Parkinson's disease: a retrospective cohort study in Taiwan |
| Q38864839 | Preclinical to phase II amyloid beta (Aβ) peptide modulators under investigation for Alzheimer's disease |
| Q38111848 | Protective arms of the renin-angiotensin-system in neurological disease |
| Q50211325 | Protective effects of telmisartan and tempol on lipopolysaccharide-induced cognitive impairment, neuroinflammation, and amyloidogenesis: possible role of brain-derived neurotrophic factor |
| Q37024759 | RAR/RXR and PPAR/RXR Signaling in Spinal Cord Injury |
| Q38371329 | Regulation by glycogen synthase kinase-3 of inflammation and T cells in CNS diseases |
| Q37157531 | Regulation of Glial Cell Functions by PPAR-gamma Natural and Synthetic Agonists. |
| Q48257894 | Regulation of peroxisome proliferator-activated receptors (PPAR) α and -γ of rat brain astrocytes in the course of activation by toll-like receptor agonists |
| Q64067591 | Regulation of the Nrf2 Pathway by Glycogen Synthase Kinase-3β in MPP⁺-Induced Cell Damage |
| Q34049241 | Role of C/EBPβ transcription factor in adult hippocampal neurogenesis |
| Q37822830 | Role of angiotensin II receptor subtype activation in cognitive function and ischaemic brain damage |
| Q47232222 | Rosiglitazone as a Modulator of TLR4 and TLR3 Signaling Pathways in Rat Primary Neurons and Astrocytes |
| Q39746277 | Rosiglitazone inhibits proliferation of renal proximal tubular cells via down-regulation of ERK and Akt. |
| Q48554941 | Rosiglitazone protects dopaminergic neurons against lipopolysaccharide-induced neurotoxicity through inhibition of microglia activation |
| Q36596156 | S-nitrosoglutathione induces ciliary neurotrophic factor expression in astrocytes, which has implications to protect the central nervous system under pathological conditions |
| Q36939320 | Serum perfluoroalkyl acids concentrations and memory impairment in a large cross-sectional study |
| Q58699276 | Signaling Mechanisms of Selective PPAR Modulators in Alzheimer's Disease |
| Q37369927 | Stress-induced neuroinflammation: mechanisms and new pharmacological targets. |
| Q37198492 | Suppression of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced nitric-oxide synthase 2 expression in astrocytes by a novel diindolylmethane analog protects striatal neurons against apoptosis |
| Q39542236 | The PPARgamma agonist pioglitazone is effective in the MPTP mouse model of Parkinson's disease through inhibition of monoamine oxidase B. |
| Q35881882 | The effect of neuronal conditional knock-out of peroxisome proliferator-activated receptors in the MPTP mouse model of Parkinson's disease |
| Q39317818 | The new iminothiadiazole derivative VP1.14 ameliorates hippocampal damage after an excitotoxic injury |
| Q36676619 | The synthetic peroxisome proliferator-activated receptor-gamma agonist ciglitazone attenuates neuroinflammation and accelerates encapsulation in bacterial brain abscesses |
| Q52343842 | Thermodynamics in Neurodegenerative Diseases: Interplay Between Canonical WNT/Beta-Catenin Pathway-PPAR Gamma, Energy Metabolism and Circadian Rhythms. |
| Q51806006 | Thiadiazolidinone-8 Ameliorates Inflammation Associated with Experimental Colitis in Mice. |
| Q36904879 | Thiazolidinediones: novel treatments for cognitive deficits in mood disorders? |
| Q35601542 | WIN 55,212-2, agonist of cannabinoid receptors, prevents amyloid β1-42 effects on astrocytes in primary culture. |
| Q42272971 | β-Amyloid exacerbates inflammation in astrocytes lacking fatty acid amide hydrolase through a mechanism involving PPAR-α, PPAR-γ and TRPV1, but not CB₁ or CB₂ receptors |
Search more.